The Buzz Surrounding: Nemaura Medical, Inc. (NASDAQ: NMRD)

Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the fiscal year ended March 31, 2022.

Corporate Highlights for FY2022:

• Commenced shipments of sugarBEAT^® continuous glucose monitor (CGM) devices to its UK licensee, MySugarWatch Limited (“MSWL”), previously DB Ethitronix Limited. MSWL commenced mass educational and awareness campaigns to physicians in the UK via a leading professional publication and direct to consumer via national papers with daily circulation exceeding 1.2 million
• Recognized $503,906 in revenue for the fiscal year ending March 31, 2022
• Signed a global commercial contract with MySugarWatch DuoPack Limited. Under terms of the deal, the Nemaura’s CGMs and sensors will be provided as Duo-Packs with prescription-only medicines that are widely prescribed for people with Type 2 diabetes. The initial Duo-Pack presentation will be launched as the first of these medicines loses its patent protection in the UK in the calendar fourth quarter of 2022. Over 2 million prescriptions are written for these medicines in the top 3 EU countries (by GDP) alone, representing a significant opportunity
• Launched beta trials of a metabolic health program using a body-worn glucose sensor along with an AI mobile application, intended for employers and insurers as well as direct to consumer, as a form of wellness and preventative medicine platform
• Tiger Partners Trading LLC, an investment advisor to Julian Robertson’s Tiger Management family office, acquired a 3.1% equity stake in the Company in February 2022
• Appointed Dr. Arash Ghadar as Chief Operating Officer. Dr. Ghadar has taken the lead in supporting the commercial supply of product to our current and future licensees and global distributors
• Completed two FDA audits in relation to the Company’s previous PMA submission and is continuing the dialogue with the FDA in relation to the PMA submission

“On the heels of successfully commercializing sugarBEAT^® in fiscal 2022 and recognizing our first revenue from our UK licensee MySugarWatch Limited, our primary goal in fiscal 2023 is to expand our revenue by supporting the launch effort of MySugarWatch Limited in the UK. We expect additional purchase orders to support the UK launch, as well as the anticipated Duo-Pack launch later in calendar 2022. MySugarWatch Limited has already begun mass advertising through education and awareness campaigns to healthcare professionals and direct to consumers through the national press,” commented Dr. Faz Chowdhury, CEO of Nemaura.

“Furthermore, we are exploring additional new channels in other territories with our technology platform. We have also started to engage with large scale manufacturers to enable us to meet the strong worldwide diabetic monitoring demand, and any appreciable scale we can build in our business should be meaningful to shareholder value. We look forward to updating investors with additional corporate highlights as they unfold,” concluded Dr. Chowdhury.

FY2022 Financial Summary:

• The fiscal year ended March 31, 2022 marked a pivotal milestone for the Company, as it commenced deliveries of sugarBEAT^® to MSWL pursuant to the initial order placed in April 2021
• Research and development expenses were consistent with the prior year at approximately $1.5 million. The Company’s historically more significant research and development expenses relating to clinical trials and improvements made to the sugarBEAT^® device began to flatten out over the 2022 fiscal year
• General and administrative expenses were $6,173,049 and $3,032,138 for the fiscal years ended March 31, 2022 and 2021, respectively. These expenses consisted of fees for legal, professional, consultancy, audit services, investor relations, insurance, advertising, and general and operational wages. The year-over-year increase in expenses were driven predominantly by increased wages, as the Company has increased headcount to support the operational scale-up process across both its UK and U.S. teams

For Full Release: https://nemauramedical.com/nemaura-medical-reports-financial-results-and-provides-business-update-for-the-fiscal-year-ended-march-31-2022/

Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs, announces today that it has secured $5 million in non-dilutive funding though a clean debt facility with no warrants or convertible elements. As part of the current financing, existing debt repayments have been deferred for nine months.

“Given the current market conditions we believe that a loan of this type with no additional dilutive terms is a testament to Nemaura’s future potential. Equally as important, it ensures we have ample cash to execute on our ambitious plans,” commented Faz Chowdhury, Nemaura’s CEO.

As of the end of March 2022, Nemaura had a cash position of $17.7 million, with current cash burn rate from business operations of approximately $1.65 million per quarter or $550,000 per month.

During the coming six months, the Company expects commercialization to ramp up, as well as to initiate multiple large-scale partnerships, to be announced as they occur. In the meantime, Nemaura began generating revenues late in 2021, and anticipates further purchase orders in the near term, thereby expanding its sales territories. In addition over the coming months the Company expects to commence generating revenues from its metabolic health program, Miboko, which utilizes its non-invasive glucose sensor along with an AI mobile application that helps users better manage diet and lifestyle habits, which received strong traction following its beta launch.

Nemaura plans to present at the H.C. Wainwright Global Hybrid Investment Conference, with its presentation being available beginning at 7:00 AM ET on May 23, 2022. Those interested in participating may register for the conference virtually here.

For Full Release:  https://nemauramedical.com/nemaura-medical-strengthens-balance-sheet-with-further-non-dilutive-funding/

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced that its CEO Dr. Faz Chowdhury will be presenting at the LD 500 investor conference on Thursday, September 3, 2020 at 10:20 a.m. ET.

In the presentation, Dr. Chowdhury will provide insight into the Company’s progress on product rollouts in the USA, Germany and UK, as well as the use of its CGM and lactate monitoring solutions for monitoring of disease progression in COVID-19 patients.

Register here: https://ld500.ldmicro.com/

“We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space.” stated Chris Lahiji, Founder of LD.

The LD 500 will take place on September 1st through the 4th.

For Full Release: https://www.businesswire.com/news/home/20200825005538/en/Nemaura-Medical-Present-LD-500-Virtual-Conference

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today issued a presentation outlining how CGM is being used by quarantined and hospitalised COVID-19 patients.

The Company has previously reported the uses of continuous lactate measurements for the monitoring of diseases progression in COVID-19 patients. Today the company issued a report outlining how CGM has been used as an effective tool for the monitoring of disease progression in both quarantined and hospitalised COVID-19 patients. This includes improvement in glycaemic control in persons with Type 2 diabetes, monitoring and managing hyperglycaemia in patients with COVID-19, and remote monitoring of glucose levels in hospitalised COVID-19 patients leading to improved quality of care without compromising the safety of medical professionals.

Both the CGM and CLM (continuous lactate monitoring) products are based on Nemaura’s BEAT™ platform, which is designed to non-invasively extract a number of analytes through the skin. By adapting the sensor chemistry, algorithm and mobile app interface initially developed for sugarBEAT®, the BEAT™ platform has the potential to be utilized for several markets beyond glucose monitoring and diabetes. Nemaura is evaluating the timelines for bringing the CLM to market as a Class 2 approved Medical Device, and the CGM device is a CE mark approved Class 2b medical device planned for launch this calendar year in the UK and Germany.

For Full Release: https://www.businesswire.com/news/home/20200819005328/en/Nemaura-Medical-Issues-Presentation-Pertaining-Continuous-Glucose

Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT™diabetes, a health subscription service designed to help people with diabetes and pre-diabetes to better manage their condition through personalized lifestyle coaching, today provided a business update and on August 14, 2020 released financial results for the quarter ended June 30, 2020.

Key Highlights:

• Strengthened balance sheet through equity based fundraise.
• Entered into letter of intent to acquire assets of Healthimation.com, a digital behavioural change programme to complement our planned proBEAT™ launch in the USA.
• Continue to make progress towards manufacture scale-up and commercial sales of sugarBEAT® in Germany and the UK, and proBEAT™ in the USA during this calendar year.
• Engaged in the adaptation of the sugarBEAT platform for continuous temperature monitoring for monitoring fever related to viral infections and other applications including facilitation of conception.
• Engaged in finalising the Continuous Lactate Monitoring system for both clinical and non-clinical applications.

Dr. Chowdhury, CEO of Nemaura Medical, commented, “We continue to make significant strides towards our commercial goals of diabetes prevention and management, and this quarter we secured sufficient capital to support our planned product launch in the USA, UK and Germany, demonstrating investor confidence in the company, its management and its product pipeline. Diabetes management and prevention is now not only actively pursued by healthcare insurers where the long term savings are substantial, but also by mainstream employers who are taking an increasingly keen interest in the health and wellbeing of their employees. With over 88 million people with pre-diabetes and over 25 million people with Type 2 diabetes in the USA we are looking forward to being part of the solution using our world first non-invasive daily-use sensor technology.”

Financial summary:

• Research and development expenses decreased to $315,312 for the quarter ended June 30, 2020, a decrease of $240,871 compared to the same quarter in 2019.

• General and administrative expenses decreased to $595,720 for the quarter ended June 30, 2020, compared with $699,008 for the same quarter in 2019.

• The Company’s comprehensive loss was $1,095,233 for the quarter ended June 30, 2020, compared with $1,267,016 for the same quarter in 2019.

• At June 30, 2020, the Company’s cash balance was $5,952,934. The Company received net proceeds of $4,618,074 from a note purchase agreement entered into on April 15, 2020 with a borrowing period of 24 months.

Our cash balance has increased further in our second quarter 2020. On July 30, 2020 we completed a fundraise with net proceeds of approximately $10.7 million, bringing our current cash position to approximately $18 million as of today.

For Full Release:  https://www.businesswire.com/news/home/20200817005267/en/Nemaura-Medical-Reports-Results-Business-Update-Quarter

Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching, today announced the pricing of a “best efforts” public offering of an aggregate of up to 1,586,206 shares of its common stock and warrants to purchase up to an aggregate of 793,103 shares of its common stock. Each share of common stock and accompanying one-half of a warrant is being sold for a combined purchase price of $7.25, for a gross deal size of $11.5 million, not including any future proceeds from the exercise of the warrants and before deducting the placement agent fees and offering expenses. The offering is expected to close on or about July 30, 2020, subject to satisfaction of customary closing conditions.

The Company further announced that the press release issued on July 27, 2020 regarding a proposed public offering was issued in error because the offering has taken the form of a “best efforts” and not an “underwritten” public offering.

Each whole warrant will have an exercise price of $8.00 per share and is exercisable immediately. The warrants will expire five years from the date of issuance. The shares of common stock and warrants can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance.

Kingswood Capital Markets, a division of Benchmark Investments, Inc., is acting as the sole placement agent in connection with the offering.

If completed, Nemaura plans to use the net proceeds from the offering for general corporate purposes, which include, but are not limited to, the commercial launch of a subscription based service for the US under the Wellness category, Lactate monitor development for launch, glucose monitoring product launch in Europe and the development of a second generation of sugarBeat.

The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (No. 333-230535) previously filed with and declared effective by the Securities and Exchange Commission (SEC) on April 8, 2019.  A final prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus, when available, may be obtained from Kingswood Capital Markets, Attention: Edward Tsuker, 17 Battery Place, Suite 625, New York, NY 10004, by telephone at (212) 404-7002, or by email at syndicate@kingswoodcm.com.  

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For Full Release: https://www.businesswire.com/news/home/20200728005557/en/Nemaura-Announces-Correction-Pricing-Public-Offering

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today issued a presentation outlining potential new applications for monitoring disease progression in Covid-19 patients using Continuous Lactate Monitoring (CLM).

The Company has previously discussed the market for athletic performance monitoring using its non-invasive continuous lactate monitor (CLM), and based on recently published independent clinical evaluations, the measurement of blood lactic acid has been established as an indicator for disease progression in Covid-19 patients. The company has issued a presentation on this subject, which can be found here: https://nemauramedical.com/wp-content/uploads/2020/07/BEAT-CLM-in-Covid19-July-2020-1.pdf

Both the CGM and CLM products are based on Nemaura’s BEAT™ platform, which is designed to non-invasively extract a number of analytes through the skin. By adapting the sensor chemistry, algorithm and mobile app interface initially developed for sugarBEAT®, the BEAT™ platform has the potential to be utilized for several markets beyond glucose monitoring and diabetes. Nemaura is evaluating the timelines for bringing the CLM to market as a Class 2 approved Medical Device.

For Full Release:
 https://www.businesswire.com/news/home/20200714005560/en/Nemaura-Medical-Evaluates-New-Applications-Continuous-Lactate

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced it has submitted its PMA application for sugarBEAT® to the United States Food and Drug Administration (FDA) through the eCopy (electronic copy) program submission process.

Nemaura’s CEO, Dr. Faz Chowdhury, commented, “The USA represents the largest single market for sugarBEAT® and submission of the PMA application is a major milestone for the Company. Whilst the PMA application is under review for approval of sugarBEAT® as a Class III medical device, we plan to launch proBEAT™ in the USA later this year. proBEAT^TM will be introduced as a wellbeing device whereby we will be collecting glucose profiles and developing artificial intelligence-based prompts and feedback on how different factors affect glucose levels to help people make informed lifestyle choices”.

The intended use of sugarBEAT® is for persons with diabetes as an adjunct to finger prick testing to monitor and track their glucose profiles, so that the user can be better informed about the factors affecting their glucose profile, and to help manage their diabetes or potentially reverse their diabetes in the case of Type 2 diabetes. sugarBEAT is targeted initially at the Type 2 diabetic population, which number is greater than 25 million people in the U.S.

For Full Release:
https://www.businesswire.com/news/home/20200707005378/en/Nemaura-Medical-Submits-PMA-Application-sugarBEAT%C2%AE-U.S.

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced an interview with its CEO Dr. Faz Chowdhury will air on The RedChip Money Report television program. The interview will air Sunday, June 28, at 3 p.m. local time on Bloomberg International, available in 100+ million homes across Europe.

In the exclusive interview, Dr. Chowdhury provides insight into the Company’s product rollout strategy, including early results from previously announced head-to-head studies with competitor CGMs.

To view the interview segment, please visit: https://youtu.be/7Mujq9_wDOw

The interview will also air in the US on the Action Channel on Sunday June 28 at 11 a.m. and is available via live stream on American Business TV.

“The RedChip Money Report” delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

For Full Release:
https://www.businesswire.com/news/home/20200626005169/en/Nemaura-Medical-Interview-Air-Bloomberg-International-RedChip

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced that its CEO Dr. Faz Chowdhury will participate in an investor webinar, hosted by RedChip Companies, on Tuesday, July 7, 2020 at 11:00 a.m. ET. A live Q&A session with Dr. Chowdhury will follow the presentation.

During the presentation, Dr. Chowdhury will provide an update on the Company’s developments including commercialization progress, US product launch, and status of collaborative partnerships, as well as update on a continuous temperature monitor (CTM) for both the diabetes and non-diabetes markets.

To register for the free webinar, please visit: https://www.redchip.com/corporate/webinar_register/64

For Full Release:
 https://www.businesswire.com/news/home/20200623005539/en/Nemaura-Medical-CEO-Participate-Investor-Webinar-QA

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced Fred Schaebsdau, MD, PhD, Vice President of Strategy and Strategic Alliances, took part as guest speaker at the DiabetesMine™ D-Data Virtual ExChange held on June 12, 2020.

Dr Schaebsdau showcased Nemaura’s sugarBEAT®, the world’s first non-invasive daily CGM for Type 2 and pre-diabetic patients, as well as the Company’s BEAT®diabetes ecosystem for supporting persons with diabetes to manage their condition better. Dr Schaebsdau discussed the versatility of the platform for continuous non-invasive monitoring, which includes temperature monitoring and monitoring other analytes such as lactate and alcohol. The presentation was well received and underscored the benefits of CGM and “time-in-range” in achieving significantly better outcomes for Type 2 and pre-diabetic patients who currently monitor their blood glucose level with test strips either infrequently or not at all.

The DiabetesMine D-Date Virtual ExChange is held biannually. This event was timed to coincide with the American Diabetes Association’s Scientific Sessions, attracting a large number of attendees, including diabetes advocates, pharma leaders, developers, clinicians, and others interested in diabetes related technologies.

For Full Release: https://www.businesswire.com/news/home/20200616005535/en/Nemaura-Participated-Guest-Speaker-DiabetesMine%E2%84%A2-D-Data-ExChange 

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced its CEO, Dr. Faz Chowdhury, will present at the Credit Suisse 2020 Virtual Diabetes Sessions on Friday, June 12, 2020 at 10:15 a.m. ET.

The Virtual Diabetes Sessions include discussions with industry experts and private and public companies developing technologies and therapeutics for diabetes. The online event will take place on June 12 and 15, in conjunction with this year’s American Diabetes Association virtual meeting.

For Full Release: https://www.businesswire.com/news/home/20200610005262/en/Nemaura-Medical-Present-Credit-Suisse-2020-Virtual

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced the Company is set to join the small cap Russell 2000^® Index and the broad-market Russell 3000^® Index at the conclusion of this year’s reconstitution of the Russell stock indexes, effective after the U.S. stock market opens on Monday, June 29, 2020, according to a preliminary list of additions posted June 5, 2020.

“Inclusion in the Russell Indexes is an important milestone and will increase the overall awareness and exposure of our stock within the investment community,” stated Dr. Faz Chowdhury, CEO of Nemaura. “Broader exposure to the investment community comes at an ideal time for Nemaura as we move forward with product sales in the coming months and quarters.”

The annual reconstitution of the broad-market Russell 3000^® Index captures 3,000 of the largest U.S. stocks, ranking them by total market capitalization. The largest 1,000 companies in this ranking comprise the Russell 1000^® Index and the next 2,000 companies constitute the Russell 2000^® Index, which together comprise the Russell 3000^® Index. FTSE Russell determines membership for its Russell US Indexes primarily by objective, market-capitalization rankings and style attributes. Based on its market capitalization, the Company qualified for membership in the Russell 2000^® index, which means automatic inclusion in the Russell 3000^® Index as well as the appropriate growth and value style indexes. Membership remains in effect for one year until the next annual reconstitution.

Russell US Indexes are part of FTSE Russell, a leading global index provider, and are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. FTSE Russell reports that approximately $9 trillion in assets are benchmarked against Russell US Indexes. For more information on the Russell 3000^® Index and Russell 2000^® Index and the Russell US Indexes reconstitution, visit the “Russell Reconstitution” section at FTSE Russell website.

For Full Release: https://www.businesswire.com/news/home/20200609005454/en/Nemaura-Medical-Set-Join-Russell-2000%C2%AE-Index